Glucocorticoid induced hyperglycaemia and the development of type 2 diabetes mellitus are major downsides to the use of steroids for the treatment of acute and chronic inflammatory diseases. In a randomised controlled trial Professor Tomlinson and colleagues working with Professor Holman and the Diabetes Trials Unit have investigated whether AZD4017, an 11ß-HSD1 inhibitor, can attenuate glucocorticoid-associated side effects on blood pressure, glycaemia, bone, and lipid metabolism, assessed after 7 days therapy in healthy men....[Read more...]
Amanda Adler and Adam Wishart present What is “The Price of Life”? Communicating cost-effectiveness to the public
Date and Time: Wednesday 1 March 2023, 4:00 - 5:00pm (UK GMT)
Venue: Hybrid event to be held in Richard Doll Building Lecture Theatre, Old Road Campus, Oxford OX3 7LF and online via Zoom/Microsoft Teams (meeting link will be sent to attendees prior to event).
To Join: This is a free event, which will be taking place both in-person and online via Zoom/Microsoft Teams....
The TriMaster patient preference study results were presented today at the 2022 IDF World Diabetes Congress in Lisbon, Portugal, with two papers published simultaneously in Nature Medicine. See https://rdcu....[Read more...]
In a wide-ranging interview Professors Rury Holman and Amanda Adler discuss the origins of the UKPDS, review the trial findings, the discovery of the post-trial glycaemic and metformin legacy effects, and reveal some of the 44-year follow-up results.[Watch interview]
The 44-year UK Prospective Diabetes Study (UKPDS) follow-up results were presented today at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden. The new data from the UKPDS, one of the longest ever studies of diabetes, show that the problems experienced by people with type 2 diabetes, including heart attacks, kidney failure and vision loss are not inevitable, with the benefits of early good blood glucose control persisting for decades....[Read more...]
The EMpagliflozin in acute MYocardial Infarction (EMMY) trial was presented today by former DTU Research Fellows, Dr Harald Sourij and Dr Abderrahim Oulhaj, at the European Society of Cardiology (ESC) Congress in Barcelona with simultaneous publication in the European Heart Journal.
EMMY aimed to investigate whether empagliflozin treatment given in addition to guideline recommended post-MI therapy, and initiated within 72 hours after percutaneous coronary intervention in people with a large acute myocardial infarction, with or without diabetes, would result in a larger decline in NT-proBNP and a larger improvement in ejection fraction....
The Royal College of Physicians has awarded Dr Rajna Golubic, an academic clinical lecturer in the DTU, as the overall national winner of the 2021 Turner-Warwick lecturer scheme for her lecture entitled “Novel treatments to improve metabolic health in obesity and type 2 diabetes: the effects of cotadutide”. The lecture included the results of a mechanistic study conducted as a collaboration between the University of Cambridge and AstraZeneca....[Read more...]
New Clinical Trial to Test Drug for Diabetes in Reducing Risk of Alzheimer's Dementia
- Lack of effective treatments for Alzheimer's dementia is one of key challenges to modern medicine and society
A new study led through a collaboration between the Diabetes Trials Unit and the Department of Psychiatry at the University of Oxford, and the global healthcare company, Novo Nordisk, will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest changes that happen in the brains of people at risk of developing Alzheimer's dementia.
The Impact of Semaglutide in Amyloid Positivity (ISAP) trial will recruit 88 volunteers currently living without dementia from five UK clinical sites in: Oxford, Imperial College London, University College London, Exeter, and Bristol....
Computer simulation models, such as the UKPDS Outcomes model 2 (UKPDS-OM2), allow users to predict disease progression, health outcomes and costs in individuals with type 2 diabetes.
Data from 5,102 UKPDS participants from the 20-year trial and 4,031 survivors with 10 years post-trial follow-up were used to derive time path equations for 13 clinical risk factors: HbA1c, systolic blood pressure, LDL-cholesterol, HDL-cholesterol, BMI, micro- or macro-albuminuria, creatinine, heart rate, white blood cell count, haemoglobin, eGFR, atrial fibrillation and peripheral vascular disease....
People who get type 2 diabetes need to gain control of their blood-sugar levels — fast. The years immediately after diagnosis are strikingly critical in terms of their future risk for heart attacks and death....[Read more...]
A new analysis of UK Prospective Diabetes Study (UKPDS) data shows that a simple blood test which estimates the degree of insulin resistance at the time of diagnosis of type 2 diabetes can help to predict the development of heart failure and death many years later.[See press release here]
This year marks the centenary of the discovery of insulin, the first peptide hormone to be identified, by Sir Frederick G. Banting and Charles Herbert Best working in John Macleod's laboratory at the University of Toronto....[Read more...]
A webinar was held on Friday 13th November 2020 at 14:00 GMT to launch The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
There were over 700 registrants from more than 49 countries.
Ahead of World Diabetes Day (14th November), The Lancet publishes a new report calling for action to close the gap in diabetes prevention and care. Worldwide, 463 million people have diabetes, with 80% from low-income and middle- income countries (LMICs)....[Read more...]
The Diabetes Trials Unit is resuming the COPCOV trial in the UK following renewed approval from UK regulators. This important global trial will answer the question whether health-care workers who take hydroxychloroquine, compared with a placebo, will have lower risk of getting COVID-19....[Read more...]
With the Mahidol Oxford Tropical Medicine Research Unit (MORU), the Diabetes Trials Unit is running the COPCOV trial in the UK. This important global trial will answer the question whether health-care workers who take hydroxychloroquine, compared with a placebo, will have lower risk of getting COVID-19....[Read more...]
COPCOV begins to enrol patients at Brighton and Sussex University Hospitals NHS Trust and at Oxford University Hospitals NHS Foundation Trust.
Prof. Rury Holman was a member of a think tank comprised of representatives from academia, industry, and regulatory agencies that was convened to consider the regulatory guidance for cardiovascular outcome trials in diabetes following the findings of trials that had been completed. The group made several recommendations for future regulatory guidance, and for cardiovascular outcome trials of glucose-lowering therapies.[See white paper published in Circulation here]
Prof. Rury Holman and Prof. Bernard Zinman (Lunenfeld-Tanebaum Research Institute, University of Toronto) were the two international speakers invited to give keynote lectures to people with diabetes, and to Oslo Diabetes Research Centre research staff, at an all-day symposium held in the recently restored Gamle Festsal at the University of Oslo Domus Academica on Saturday 8th February 2020.
An enhanced version of the UKPDS Outcomes Model© (OM2) software was released today.
* Comparison of up to 25 treatment groups simultaneously
* New outputs showing convergence, and costs and disutilities split by event
* Generation of outputs for up to five user defined composite outcomes
* Major speed improvements....
The HOMA2 Calculator now supports the new Mac OS X Catalina. The standalone application has been updated to 64 bit on the Mac....[Read more...]
Congratulations to Dr Amanda Adler, DTU Director who has been conferred the Oxford University title of Professor of Diabetic Medicine and Health Policy.
Rury Holman, Chair of the Hellmut Mehnert Award Committee since 2014, presented this prestigious award to Lars Rydén, Senior Professor of Cardiology, Karolinska Institute, Stockholm, Sweden, and to Professor Markolf Hanefeld, Director of the Centre for Clinical Studies, Technical University, Dresden, during the 5th CVOT Summit of the D&CVD EASD Study Group in Munich, Germany. [Left to right: Prof. Eberhard Standl (D&CVD EASD Study Group Vice President), Professor Lars Rydén, Professor Mehnert (now 91), Professor Rury Holman and Professor Markolf Hanefeld]
The Hellmut Mehnert Award was founded in 1998 and named in recognition of Professor Mehnert's lifetime contributions to diabetes care, research and education, and of his service on the WHO Panel of Experts on Diabetes....
Four members of DTU attended the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona to present accepted abstracts.
Shishi Xu, a visiting researcher from West China Hospital of Sichuan University, presented a risk prediction model for new-onset type 2 diabetes in an Asian population in a poster titled 'Predicting risk of new-onset type 2 diabetes (T2D) in Chinese people with coronary heart disease and impaired glucose tolerance'....
Rury Holman, who founded the Diabetes Trials Unit in 1985, has stepped down as its Director after 34 years in the role. He will continue his academic activities as Emeritus Professor of Diabetic Medicine, whilst management of the Unit will pass to his successor, Dr Amanda Adler.
The event, held on Wednesday, 12th June 2019, in the Terrace Pavilion of the House of Commons at the Palace of Westminster, was a celebration of NICE's success over the past 20 years and a look ahead to the future.
Around 200 invited guests came from a broad range of national and local organisations along with individuals and parliamentarians who work alongside NICE and take a real interest in the work the institute does, including Royal Colleges, patient groups, industry bodies and academic institutions....
The Diabetes Trials Unit is delighted to welcome Dr Amanda Adler as the incoming DTU Director, taking over from Professor Rury Holman in September 2019.
Dr Adler chairs a Technology Appraisal Committee with the National Institute for Health and Care Excellence (NICE), and also chaired their National Guidelines Committee for Newer Agents for Type 2 Diabetes and the Quality Standard for Diabetes for England....
On Tuesday 26th March 2019 Prof. Rury Holman gave an invited keynote lecture entitled "Cardiovascular Outcome Trials in Type 2 Diabetes - Lessons Learnt and Future Directions". This symposium, addressing "Diabetes: Disarming the Silent Killer", was held in Kuala Lumpur, Malaysia....[Read more...]
Professor Rury Holman is the first recipient of the Robert Turner Award for Research Impact given for his outstanding work on the UKPDS study by Diabetes UK during their annual Professional Conference in Liverpool. The award was presented by Professor Andrew Hattersley at a ceremony held on Thursday 7th March 2019.
DTU Trial Manager Elena Villarreal worked in collaboration with three other Trial Managers from the Department of Psychiatry, the Clinical Trial Service Unit and Epidemiological Studies Unit, and the Surgical Interventions Trial Unit to host a landmark careers event on the 23rd January 2019 for non-clinical staff working in clinical trials. The event was generously funded by the NIHR Oxford Biomedical Research Centre and the Thames Valley and South Midlands Clinical Research Network (CRN)....[Read more...]
The newly updated DTU website now includes a webpage for each of our trials.
For ongoing trials, you can find out what type of participants we are looking for and contact details if you are interested in taking part....
Professor Rury Holman was declared a Living Legend at the 2018 annual joint European Society for Cardiology (ESC) and Cardiology and Diabetes (CAD) conference in Mumbai, India, on Saturday 6th October (only the second diabetologist to be given this honour) along with Dr Bernard Gersh, a cardiologist and Professor Emeritus of Medicine at the Mayo Clinic College of Medicine, Minnesota, USA
Prof Rury Holman is the recipient of the 2018 Outstanding Achievement in Clinical Diabetes Research Award by the American Diabetes Association. This award recognizes exceptional contributions in patient-oriented or clinical outcomes research that have had a significant impact on diabetes prevention and treatment....[Read more...]
Diabetes UK have released their first ever Research Impact Report which explores the impact of Diabetes UK research over the last 80 years. It was launched at a reception held on Thursday 15th March 2018 at the Diabetes UK Professional Conference....[Read more...]
After 10 years at the Diabetes Trials Unit (DTU), Dr. Angelyn Bethel is leaving to pursue career opportunities in the pharmaceutical industry.
Dr. Bethel has the following message for her friends and co-workers: “My decision to leave the DTU was not taken lightly....
Launched on 1st March 2018, we expect results from this trial will be available in 2020.
The REF is a system for assessing the quality of research in UK higher education institutions implemented for the first time in 2014.
Defining type 2 diabetes in the United Kingdom
Planning for a future with diabetes: tools to assess diabetes risk and outcomes
The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) is a trial that assessed the long-term cardiovascular safety and efficacy of once-weekly exenatide, administered in patients with type 2 diabetes who had a wide range of cardiovascular risk. In this video, Professor Rury Holman shares his insights into the trial results.[Watch video]
The ACP Journal Club has identified EXCSEL as an original study that warrants immediate attention by physicians attempting to keep pace with important advances in internal medicine.[Click here to see review]
On Wednesday December 6th, Professor Angelyn Bethel presented new data from the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). The invited talk, presented within the "Latest Cardiovascular Clinical Trials" symposium, shared a new meta-analysis of the four glucagon-like peptide-1 receptor agonist cardiovascular outcome trials conducted to date....[Read more...]
A total of 7534 delegates from 182 countries attended the 2017 IDF Congress in Abu Dhabi.
On Wednesday 6th December, Professor Rury Holman gave an invited talk in the "Latest Cardiovascular Clinical Trials" symposium....
Dr Ernesto Maddaloni from the University Campus Bio-Medico, Rome, Italy is one of five Mentees selected for the new European Foundation for the Study of Diabetes (EFSD) Future Leaders Mentorship Programme, with Professor Rury Holman as his Mentor.
During his inagaural visit to the Diabetes Trials Unit he gave an invited talk hosted by Prof. Holman on Wednesday 18th October 2017 in the OCDEM Seminar Series entitled "The Bone-vascular Axis: Insights from Adults with Autoimmune Diabetes"....
Professor Rury Holman gave a lecture entitled "New Results from the ACE Trial" during the opening session of the 28th Great Wall of China International Congress of Cardiology (GW-ICC) in Beijing on Friday 13th October 2017. The meeting was attended by 20,285 delegates from 35 countries....[Read more...]
The Macintosh version of the HOMA2 Calculator has been updated to version 2.2.3 to include support for Excel 2016. The HOMA API has also been updated to include support for R....[Read more...]
Professor Rury Holman gave an invited plenary lecture in Hong Kong on Sunday 1st October 2017 at the 19th East Meets West Symposium focussing on Diabetes & Cardiovascular Risk Factors. His lecture, entitled "Updates on recent cardiovascular outcome studies in diabetes - from ACE to EXSCEL", reprised the key findings from the ACE trial and EXSCEL, first presented at the EASD in Lisbon on September 13th and 14th 2017 respectively.
The Macintosh version of the UKPDS Risk Engine has been updated to enable it to run on MacOS X (Intel 32/64 bit) and with Microsoft Excel 2011/2016 or later.[Download]
Professor Rury Holman presented the recently released results of the ACE trial at a series of meetings with senior endocrinologists and cardiologists in Shanghai, Beijing, Chengdu, Wuhan and Guangzhou between Sep 24th and 28th. The Beijing Summit meeting, with two-way video links to 20 other Chinese cities, was compèred by the Chinese journalist, Yang Lan....[Read more...]
Diabetes is a widespread and increasing problem currently affecting 30.3 million Americans, 4.5 million people living in the United Kingdom, and 422 million people worldwide. In 2015, an estimated 1.6 million deaths worldwide were directly caused by diabetes....[Read more...]
People with coronary heart disease and impaired glucose tolerance are at increased risk of future cardiovascular events, and of developing type 2 diabetes. In 2006, 37.3% of Chinese adults hospitalised for coronary artery disease had impaired glucose regulation, a major risk factor for diabetes....[Read more...]
The first patient has been randomised into the TICSI trial.
The topline results for the EXSCEL study have been released by AstraZenca.[Click here to see press release.]
Professor Rury Holman gave an invited lecture on Monday 8th May 2017 at the Hong Kong Institute of Diabetes and Obesity, Chinese University of Hong Kong, in their Distinguished Lecture Series on Diabetes IV.
The lecture, entitled "The legacy of the United Kingdom Prospective Diabetes Study", provided the historical perspective to the 20-year trial and the 10-year post-trial monitoring period, and highlighted the major findings that have since been a major influence on clinical practice....
Every day clinicians and scientists at the Boris Family Clinic help people deal with their diabetes and look for new solutions to this common disease. Now they are using a novel approach: a music video....[Read more...]
Clinicians and researchers are preparing to light Oxford's Magdalen Tower blue to mark World Diabetes Day - and have invited patients and visitors to then learn more at an open day about the condition at the Churchill Hospital.
The tower at Magdalen College in High Street will follow in the footsteps of other landmarks including Elizabeth Tower (known informally as Big Ben) and Sydney Opera House by turning blue between 4.30pm and 10pm on Monday, November 14, World Diabetes Day....
Few data are available on the potential benefits that achieving different HbA1c targets might deliver. Dr Samiul Mostafa, a Diabetes Trials Unit academic clinical lecturer, used the UKPDS Outcomes Model to estimate 10-year risks for micro- and macrovascular type 2 diabetes complications when targeting HbA1c levels between 10% and 6%, to quantify the likely incremental benefits....[Read more...]
In a landmark report released on 14th September 2016, the United Nations called on governments worldwide to pass legislation requiring clinical trials to be registered, and their methods and results to be fully reported. The report, authored by a high-level panel appointed by UN Secretary General Ban Ki-moon, explicitly calls for clinical trial study designs, protocols, data sets, and test results to be made publicly available....[Read more...]
RDM researchers have uncovered new genetic evidence of how the benefits of the world's most commonly used Type 2 diabetes drug may vary between individuals.
Metformin, a drug used by hundreds of millions of people with Type 2 diabetes worldwide, has been in use for over 50 years....
The International Consortium of Investigators for Fairness in Trial Data Sharing have published a response to the The International Committee of Medical Journal Editors (ICMJE) proposed plan for sharing data from randomized, controlled trials (RCTs). This plan will require, as a condition of acceptance of trial results for publication, that authors make publicly available the deidentified individual patient data underlying the analyses reported in an article....[Read more...]
Dr Samiul Mostafa, DTU Honorary Clinical Lecturer, has received funding from The Academy of Medical Sciences for his project "Determining the 'sweet-spots' for cardiovascular risk factors in Type 2 Diabetes Mellitus"
An article in the Summer edition of Diabetes Update highlights the importance of reducing cardiovascular risk in people with diabetes using data from recent clinical outcome trials, several of which were conducted by the Oxford Clinical Trial Service Unit and by the Diabetes Trials Unit.[View the PDF]
Following on from the recent highly-successful EXSCEL investigator meetings in Shanghai, Seoul, and Rio de Janeiro, further meetings were held this week for US and Canadian sites in Denver, US, and for European sites in Riga, Latvia. In Denver there were 89 attendees with a further 70 people online, while 142 folk came to Riga....[Read more...]
The NIHR has produced a video highlighting the role that Clinical Trials Units (CTUs) play in developing an NIHR funding application, explaining both the role and benefits of working with CTUs.
CTUs are specialist units which have been set up with a specific remit to design, conduct, analyse and publish clinical trials....
The first edition of the 2016 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[View the PDF]
The fourth edition of the 2015 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[View the PDF]
The third edition of the 2015 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[View the PDF]
I am delighted to report that Jyothis George has received the Clinical Science Award (for best oral presentation) at this year's European Society of Human Reproduction and Embryology (ESHRE) meeting held in Lisbon based on his clinical trial of a Neurokinin B antagonist in polycystic ovary syndrome.[Link]
DTU Deputy Director Angelyn Bethel is replacing Prof. Rury Holman as Joint Chair of GLINT with Prof. Nick Wareham. Prof. Holman will continue to support the study in the role of Chief Adviser.
A slide set displaying the primary results of TECOS, as presented at the ADA on Mon 8th June 2015, is freely-available for download via the link below.
The TECOS study group presented the primary results today to an audience of over 6,500 attendees at the 75th Annual Scientific Sessions of the American Diabetes Society in Boston, Massachusetts, US.
The updated software for the new and fully revised second version of the UKPDS Outcomes Model© (OM2) was released today.
The UKPDS Outcomes Model© is a computerised simulation tool designed to estimate Life Expectancy, Quality Adjusted Life Expectancy and the cumulative costs of complications in people with type 2 diabetes mellitus (T2DM)....
Men with type 2 diabetes often have low levels of testosterone, which may be associated with an increased risk of cardiovascular problems. A 12-week study being run by the DTU Translational Trials Group is investigating whether a hormone called kisspeptin, which controls the release of testosterone, can restore more normal testosterone levels....[Read more...]
The second edition of the 2015 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[View the PDF]
The European Association for the Study of Diabetes (EASD) was founded 50 years ago, in 1965.
See link below for details.
Professor Roy Taylor and Professor Rury Holman hypothesise that each individual has a personal fat threshold (PFT) which, if exceeded, makes likely the development of T2DM.[Link]
This DRWF Newsletter provides an update on a proposed new version of the HOMA Calculator. This is being developed to estimate beta cell function and insulin sensitivity in people with type 2 diabetes who are treated with insulin....[Read more...]
The first GLINT participant was enrolled on 10th March 2015. The feasibility phase of GLINT is planned to continue until November 2015, recruiting 500 participants in total.
The TECOS primary results will be presented at the 2015 ADA 75th Scientific Sessions in Boston, US, on the afternoon of Monday 8th June at 4:30 pm.
The first edition of the 2015 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[View the PDF]
The fourth edition of the 2014 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[View the PDF]
Professor Rury Holman has been identified as one of the top-400 living core biomedical researchers, based on a normalized score combining total citations and h-index, in a paper published in the European Journal of Clinical Investigation. In total, 8 University of Oxford biomedical researchers are listed.[Link]
Professor Rury Holman gave an invited lecture at the Australian Diabetes Society Annual Scientific Meeting on Wednesday 27th August 2014 which was attended by over 1,900 delegates.
His talk, entitled "How can we Reduce Residual Cardiovascular Risk in T2DM?", outlined five possible approaches to reducing the gap between the elevated cardiovascular risk seen even in well-treated people with diabetes and their non-diabetic peers.
Thomson Reuters report, "The world's most influential scientific minds: 2014", lists 3,200 individuals across 21 fields who have published the highest-impact work that is most frequently acknowledged by their peers. These papers rank in the top 1% by citation for their field and year of publication....[Read more...]
The third edition of the 2014 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[View the PDF]
A meeting entitled "Update in diabetes: new drugs, new technology, new models of care" was held by the Royal College of Physicians (London) on Thursday 5th June 2014.
This included the debate: "Sulfonylureas should not be used routinely as second line treatments for patients with Type 2 Diabetes"
For: Dr Robert Ryder, Sandwell and West Birmingham Hospitals NHS Trust
Against: Professor Rury Holman, University of Oxford
The motion was defeated.
The 2014 Oxford Biomedical Research Centre annual open day was held on Monday May 19, with teams demonstrating the latest technology and techniques tackling conditions such as cancer, dementia, arthritis and diabetes.
Staff from the Diabetes Trials Unit (DTU) Translational Research Group (TRG) were on hand to provide advice and insights into diabetes and the metbolic impact of different foods....
On Friday 9 May, DTU Clinical Researcher Dr Matthew Wintle gave the invited Bill Williams Memorial Lecture at the Spring Meeting of the Society of Physicians in Wales. Around 60 clinicians who manage and deliver general medicine and speciality clinical services in hospitals across Wales travelled to the beautiful village of Portmeirion for the meeting....[Read more...]
Congratulations to DTU Senior Clinical Researcher Dr Michael Theodorakis, who has become a Fellow of the Royal College of Physicians (FRCP), the highest level of membership awarded by the College.
Michael joined the DTU in July 2012, and is the Clinical Lead for the Acarbose Cardiovascular Evaluation (ACE) trial....
The second edition of the 2014 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[View the PDF]
In a personal view article published online today in the journal The Lancet Diabetes & Endocrinology, researchers are calling for the systematic evaluation of heart failure to be included routinely in clinical outcome trials of glucose-lowering drugs.
Lead author Prof John McMurray of the University of Glasgow, together with DTU Director Prof Rury Holman and colleagues from Canada and the USA, are concerned that heart failure is rarely considered as a key outcome, or even part of composite cardiovascular outcomes, in large-scale clinical trials of glucose-lowering drugs....
Congratulations to our senior clinical researcher Dr Jyothis George, who has been appointed as a Robert Turner Research Associate until December 2014 at Green Templeton College (GTC), University of Oxford.
Jyothis is a Clinical Lead for one of our international mega trials, EXSCEL (EXenatide Study of Cardiovascular Event Lowering), works on early phase studies with the DTU Translational Research Group, and is a diabetologist in OCDEM....
Professor Rury Holman gave a special invited lecture at the 35th annual meeting of the Diabetes Association and the Endocrinology Society of the Republic Of China (Taiwan) on Sunday 2nd March 2014. Over 900 endocrinologists attended the meeting in Taipei....[Read more...]
We are delighted to announce that Dr Matthew Wintle has joined the Diabetes Trials Unit (DTU) as a Clinical Researcher.
Matthew has joined us from Amylin Pharmaceuticals in California, where he was Global Medical Director....
Today we release the latest software version of our HOMA2 Calculator, which enables researchers to quickly assess the level of insulin resistance and how well beta cells are working in people with diabetes.
This new update (version 2.2.3) means the software can now support Mac OS X Lion or later....
On 23rd January 2014, DTU Director Professor Rury Holman led an OCDEM Industry Networking Event to showcase translational diabetes research in Oxford and bring leading academics and R&D companies together to foster new collaborations.
Nearly 40 attendees, including Oxford basic science, translational and clinical researchers and representatives from national and international life sciences companies (including pharma, med tech and biotech) came together to hear about some of the exciting diabetes research programmes being undertaken in OCDEM, before moving to Oriel College for a drinks reception and networking dinner....
DTU Director Prof Rury Holman gave the plenary talk at this year's OCDEM day, held on Friday 24th January.
Entitled "Putting the UK Prospective Diabetes Study into perspective", Prof Holman showed how, 15 years since its initial publication, this ground-breaking study is still as relevant to the diabetes community as it ever was....
The first edition of the 2014 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[Link]
The DTU has today launched it's new website. The new site provides a more modern look, Radcliffe Department of Medicine branding and a simpler navigation system.
Professor Rury Holman gave an invited plenary lecture at the International Diabetes Federation (IDF) 2013 World Diabetes Congress in Melbourne, Australia on 4th December. More than 10,000 people from across the globe attended the conference....[Read more...]
The fourth edition of the 2013 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[Link]
The Myre Sim Award is made biennially by The Royal College of Physicians of Edinburgh. Dr Jyothis George was presented today with second prize for best original first author paper in a peer-reviewed journal between 1 March 2011 and 15 January 2013 inclusive.[Link]
We are delighted to announce that Dr Jyothis George has joined the Diabetes Trials Unit (DTU) as a Senior Clinical Researcher.
Jyothis has moved from the University of Edinburgh, where he completed his PhD and specialist training in diabetes, endocrinology and internal medicine....
The third edition of the 2013 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[Link]
The new UKPDS-OM2 has significant advantages over the existing model, as it captures more outcomes, is based on longer follow-up data, and more comprehensively captures the progression of diabetes. Its use will permit detailed and reliable lifetime simulations of key health outcomes in people with type 2 diabetes mellitus....[Read more...]
On 27th May 2013 Professor Holman gave a talk entitled "New Understanding of the UKPDS 'Legacy Effect'" at Tongren Hospital, Beijing, China following his appointment in December 2012 as Visiting Professor to Capital Medical University.
Prof Holman gave one of the two Special Lectures at this year's Japanese Diabetes Society meeting in Kumamoto, Japan on May 17th.
His talk was entitled "Clinical Outcome Trials in Type 2 Diabetes".
The second edition of the 2013 TRG newsletter is now available. Click the link below to find out about our work and recent activities:[Link]
2012 was an exciting year for TECOS that saw the close of recruitment following randomisation of over 14,700 participants. Of the participating countries, 21 of 38 met or exceeded their recruitment targets....[Read more...]
Research published online this week by DTU and Australian researchers has found that one in six people with newly-diagnosed type 2 diabetes may have experienced a silent myocardial infarction (SMI) - a heart attack without chest pain or symptoms - in the past.
Published in the journal Circulation, the study examined data from 1,967 people with type 2 diabetes who enrolled in the landmark 30-year UK Prospective Diabetes Study (UKPDS)....
The spring edition of the TRG newsletter is now available. Click the link below to find out about our work and recent activities:[Link]
Research published online today led by DTU researchers has found that people may be able to test themselves for diabetes in the comfort of their own home, using a novel electronic screening device.
The study, performed by DTU's NIHR supported Translational Research Group (TRG), is published in the journal Diabetes Care....
The Diabetes Trials Unit (DTU) has joined the Radcliffe Department of Medicine, a large new multidisciplinary department within the Medical Sciences Division of the University of Oxford.
Led by Professor Hugh Watkins, the RDM aims to advance our understanding of medical conditions at the basic level and apply this knowledge to clinical care....
November has seen Professor Rury Holman give several invited talks at global meetings in Chile and the USA.
On 12th November, he gave three talks at the XXXI World Congress of Internal Medicine - two talks about therapies for type 2 diabetes, and one about hyperglycaemia and cardiovascular risk....
A new video from the Diabetes Trials Unit (DTU) at the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) is being launched today, on World Diabetes Day.
Produced with local film company Nice Tree Films and funding from the NIHR Biomedical Research Centre in Oxford, the video features DTU Deputy Director Dr Angelyn Bethel and research nurse Sarah White encouraging people to take part in clinical trials and get involved with research at OCDEM....
The autumn edition of the TRG newsletter is now available. Click the link below to find out about our work and recent activities:[Link]
Oxford University has retained its position as best in the world for medicine, in the Times Higher Education World University Rankings. The University as a whole came joint second in the world....[Read more...]
DTU Director Professor Rury Holman was elected as the first China Initiative for Diabetes Excellence (CIDE) program Visiting Professor on 21st September 2012, and gave four invited talks at their two-day meeting in Hangzhou, China.
The CIDE program, which received a 5-year grant under the auspices of the Chinese Ministry of Health, is run in collaboration with the Chinese Diabetes Society (CDS), the Chinese National Center for Chronic and Noncommunicable Disease Control and Prevention (CDC), the World Health Organisation Collaborating Center for Diabetes Education, Translation and Computer Technology (WHO), and the International Diabetes Center (IDC) & Mayo Clinic....
We are delighted to announce that the DTU's full registration by the UK Clinical Research Collaboration (UKCRC) has been renewed, which enables us to continue to work as a UKCRC Clinical Trials Unit.
The award recognises clinical trials units that have the expertise to centrally coordinate high quality multi-centre clinical trials, and aims to help improve the quality and quantity of available expertise in the UK....
The summer edition of the TRG newsletter is now available. Click the link below to find out about our work and recent activities:[Link]
Research published online this month led by researchers at the University of Oxford, including DTU, suggests that the diabetes drug metformin does not prevent people from developing cancer.
The study, funded by Diabetes UK and published in the journal Diabetologia, analysed the largest collection of clinical trials data ever used to study metformin and cancer....
The eighth OCDEM / Young Diabetologists' Forum (YDF) Finishing School was held at Eynsham Hall, Oxford on 21 and 22 June, chaired by Professors Rury Holman and Edwin Gale.
Fifteen specialist registrars came from all over the UK to listen to talks and attend workshops by diabetes experts about complex clinical issues in diabetes and to receive advice about how best to manage the transition to consultant status....
We are delighted to announce that Dr Michael Theodorakis joined the Diabetes Trials Unit (DTU) as a Senior Clinical Researcher on 1st July.
Michael has relocated from Athens, Greece, where he was a member of the medical faculty at the University of Athens Medical School, and also a clinician at the Endocrinology, Metabolism and Diabetes Unit, University of Athens....
We are delighted to announce that more than 14,000 patients have now been recruited to the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) trial.
Investigators from across the globe joined the TECOS management team to celebrate reaching this milestone at the American Diabetes Association (ADA) conference in Philadelphia, USA on Saturday 9th June....
Several DTU staff presented their work at the American Diabetes Association (ADA) conference in Philadelphia, USA, this week.
DTU Director Prof Rury Holman presented a late-breaking poster on Sunday 10th June showing that the apparent rapid increase in glucose levels thought to occur just before diabetes is diagnosed may be an artefact....
DTU Director Professor Rury Holman gave an invited talk at the first joint China Medical Tribune and American Diabetes Association (ADA) symposium - 'A Perspective on "Metabetes" from China' - in Philadelphia, USA on Saturday 9th June.
His talk updated attendees about the rationâle for the Acarbose Cardiovascular Evaluation (ACE) Trial, its design, and progress to date....
DTU Director Professor Rury Holman, Head of Development Joanne Keenan and Head of Clinical Research Zoe Doran have accompanied Oxford's Vice-Chancellor Professor Andrew Hamilton and researchers from the Nuffield Department of Medicine (NDM) on a visit to China.
The team took part in an event in Beijing on 14th May to celebrate Oxford University and China's research collaborations in the field of medical sciences....
A clinical trial run by DTU's Translational Research Group (TRG) has featured in the local media in the hope that it encourages people to take part.
Funded by the British Heart Foundation, the study aims to find out if changing the way we give aspirin to people with type 2 diabetes could help protect them from heart attacks and strokes....
Professor Rury Holman gave the opening keynote speech at the 4th annual Asian-Pacific Bayer Chinese Diabetes (ABCD) meeting in Chengdu, China on Saturday 12th May.
Prof Ji Linong, President of the Chinese Diabetes Society, introduced Prof Holman's talk describing "Early Intervention Strategies for Type 2 Diabetes"....
We are delighted to announce that Professor Rury Holman has been elected as a Fellow of the prestigious Academy of Medical Sciences, for his outstanding contribution to medical science.
Professor Holman joins 45 other leading researchers from around the UK, including five other Oxford researchers, to be elected as Fellows of the Academy this year....
Professor Rury Holman was invited to speak at the 15th International Congress of Endocrinology (ICE), held in conjunction with the 14th European Congress of Endocrinology, on Sunday 6th May.
This year's conference in Florence, Italy, was the largest ever European Endocrinology meeting with more than 5300 delegates attending and presenting 2012 abstracts....
Professor Rury Holman gave an invited talk at the 22nd annual European Meeting on Hypertension and Cardiovascular Protection on Sunday 29th April.
His talk at the ICC in London, entitled "Ongoing Randomized Trials for Cardiovascular Protection with Incretin Drugs", was given during a session exploring the effects of glucose lowering drugs on cardiovascular risk....
Congratulations to our senior clinical researcher Dr Harald Sourij, who has been appointed the Robert Turner Research Associate for one year at Green Templeton College (GTC), University of Oxford.
Harald is the Academic Clinical Lead for one of our international megatrials, EXSCEL (EXenatide Study of Cardiovascular Event Lowering)....
Together with others, DTU researchers have confirmed that a variation in a gene called ATM could help to explain why some people have a better response to a first-line drug for type 2 diabetes called metformin.
This study, which confirms work published previously in Nature Genetics, has examined an additional population of over 1000 people taking metformin in the UK and the Netherlands....
Professor Rury Holman gave a keynote talk at the Second Annual PharmaCoEconomics Middle East Forum in Abu Dhabi on 23rd March.
His talk described how the UKPDS model can quantify the burden of type 2 diabetes by simulating and predicting its many complications, with their different impacts on quality of life and different cost consequences, over a lifetime....
Several groups within the Oxford Biomedical Research Centre (BRC) Diabetes Theme took part in this year's public open day which was held on the 14th March in the Churchill Hospital.
This third annual event was filled with enthusiastic patients, members of the public and healthcare professionals all there to learn more about local science and medicine....
We are delighted to announce that Dr Angelyn Bethel will become the new Deputy Director of the Diabetes Trials Unit (DTU) from 5th March.
Angelyn joined the DTU in 2008 from Duke University Medical Center in Durham, NC, USA....
Professor Rury Holman gave an invited keynote talk at the annual Novo Nordisk Diabetes Update (NNDU) in Tianjin, China on Sunday 12th February.
More than 400 Chinese senior endocrinologists attended his talk, "Warning signals from clinical trials: all that glitters is not gold
", where he described the importance of clinical trial design and how trial results should always be reported in context....
In an analysis of the British Regional Heart Study and the British Women´s Heart Health Study, Wannamethee and colleagues report that women develop diabetes at higher BMIs than men.
This is, however, a well-recognised finding demonstrated in 1988 by the UK Prospective Diabetes Study (UKPDS), and later confirmed by a study using a US database....
In an age of media saturation and information overload, it is becoming more difficult to discern real health and safety signals from background noise.
In Diabetes Voice, Prof. Rury Holman argues that the future of medicine relies on effective clinical trials and competent reporting....
In 2008, the US Food and Drug Administration (FDA) issued guidance which means that all antidiabetic drugs to be licensed in the future require thorough assessment of cardiovascular safety.
In Current Cardiology Reports, we review the circumstances from which the FDA guidance arose, and examine the differences in clinical trials registered on ClinicalTrials....
Professor Holman gave two invited talks, entitled "Legacy Effect of Improved Glycaemic Control in Type 2 Diabetes" and "Estimating Individual CVD Risk in Type 2 diabetes", at the International Diabetes Federation World Diabetes Congress 2011 meeting in Dubai on Tuesday 6th December.[Link]
Professor Holman gave an invited talk entitled "Acarbose: The comeback kid?" at the American Heart Association Scientific Sessions 2011 in Orlando on Sunday 13th November 2011.[Link]
Professor Holman gave an invited talk entitled "Acarbose: The comeback kid?" at the 39th Meeting of the British Society for Paediatric Endocrinology and Diabetes (BSPED) in London on Friday 11th November 2011.
Professor Holman gave a plenary talk entitled "Key Messages from Cardiovascular Trials in T2DM" at the 13th Canadian National Atherosclerosis Forum on Friday 14th October 2011.
Professor Holman gave a keynote speech entitled "From Research Fellow to International Researcher" at the YDF Research day at the University of Warwick on Thursday 29th September 2011. He also gave another, entitled "You and your supervisor - the supervisor's perspective", the following day at a mentoring session for doctoral students.
On the morning of 14 September, Professor Rury Holman gave an invited plenary talk in the session 'Warning signals from clinical trials: all that glitters is not gold' at the 47th meeting of the European Association for the Study of Diabetes (EASD), held in Lisbon, Portugal. In his lecture, entitled 'Seeking the truth', he discussed the need for a systematic approach to assessing rapidly evolving data from a myriad of sources that have variable provenance when assessing possible drug-related benefits and harms....[Read more...]
Research at the Diabetes Trials Unit is set to benefit from renewed funding of the Oxford Biomedical Research Centre (OxBRC) by the National Institute for Health Research (NIHR). The OxBRC was recently awarded £95m, an increase of 50% on the previous allocation, to support translational research....[Read more...]
This year's Acarbose Cardiovascular Evaluation (ACE) Regional Investigator Meetings were held between 14th and 21st July in six Chinese cities: Beijing, Chengdu, Hangzhou, Guangzhou, Qingdao and Wuhan. We were thrilled by the high attendance, excellent interaction and the interest in the trial shown by Chinese clinicians....[Read more...]
On Friday 15th July 2011 Oxford University (Beijing) Science & Technology Company Ltd. (OUBST) opened its new suite of offices in Beijing's Central Business District....[Read more...]
In Diabetes, Obesity and Metabolism, we investigate how insulin treatment satisfaction varies between biphasic, prandial or basal insulin treatment groups in the Treat-To-Target in Type 2 diabetes (4-T) trial.
In total, 708 patients taking metformin and sulfonylurea were randomized to biphasic, prandial, or basal insulin....
The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial was successfully launched outside of the US in May this year, with four Investigator Meetings conducted in May and June in order to initiate sites.
The first of those investigator meetings took place in Sydney, Australia on 4th May and was closely followed by a meeting in Hong Kong on 6th May for sites in Asia-Pacific....
Professor Rury Holman has been awarded the American Diabetes Association's prestigious 2011 Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes.
The award, named after former president of the American Diabetes Association Dr. Rifkin, is given to individuals whose outstanding service in the cause of diabetes has been performed with an international perspective and provided global impact....
In Diabetes Care, we describe how withdrawing rosiglitazone and ramipril medication affects diabetes incidence after the closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
A set of 3,366 subjects who had not developed diabetes by the end of the trial, but who had been taking double-blinded medication, were transferred to single-blinded placebo for 2 to 3 months, and their glycaemic statuses analysed....
In the past, qualitative trial research has mainly focused on whether patients and staff understand how trials work, or tried to understand their motivations for taking part. Rarely has research looked into why treatment recommendations are followed, or not, during the trial....[Read more...]
ADOPT (A Diabetes Outcomes Prevention Trial) showed that initial treatment with just rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. In CJASN, we examine the differences in albumin excretion, renal function and blood pressure over the course of 5 years between the treatment groups....[Read more...]
On the 24 March 2011, the TECOS team arrived in Prague to host the initiation meeting for the new sites in Europe, Israel and South Africa.
The event covered academic issues as well as the operational management of TECOS....
Part of the Treating to Target in Type 2 Diabetes (4-T) trial involved exploring participants' reactions to their intensifying insulin therapy.
In Diabetic Medicine we, along with Nick Jenkins & Julia Lawton of the University of Edinburgh, present a series of qualitative interviews from the trial with participants who had had their insulin therapy intensified....
The ADOPT study (A Diabetes Outcomes Prevention Trial) showed that treatment with rosiglitazone alone provided somewhat more effective glycaemic control than metformin or glyburide alone, in patients with recently diagnosed type 2 diabetes. In a paper published recently in Diabetes, we examined changes in β-cell function and insulin sensitivity among the three treatments in ADOPT....[Read more...]
Professor Rury Holman has been appointed as a Senior Investigator by the National Institute for Health Research (NIHR).
A total of 200 NIHR Senior Investigators make up the NIHR College, a selection of some of the UK's most outstanding healthcare researchers....
The third YDF OCDEM Finishing School for Specialist Registrars was held at Eynsham Hall on 10th and 11th February 2011. Thirty six final year SpR's - from as far afield as Scotland, Manchester and Yorkshire - met for a meeting that covered complex clinical issues in the management of people with diabetes and provided preparation for securing and starting a consultant post....[Read more...]
Professor Holman gave an invited talk entitled "Management of Type 2 Diabetes in the 21st century" at the Royal College of Physicians Advanced Medicine Conference in London on Wednesday 16th February 2011.
Informing a person of their risk of developing a disease might be sufﬁicient impetus to change that person's lifestyle.
This study looked to determine if a personalised 10-year cardiovascular disease (CVD) risk estimate could increase physical activity and other risk reduction behaviours in adults at high risk of CVD....
The 2011 YDF-OCDEM Finishing School for Specialist Registrars (an Advanced Diabetes Course, previously known as the YDF-OCDEM State of the Art Course) will be held on 10th and 11th of February at Eynsham Hall near Oxford.
The course will be chaired by Professors Rury Holman and Edwin Gale and is designed for those coming towards the end of their Specialist Registrar training, soon to embark on consultant careers....
Corrected smoking status check and amputation output and added cohort outputs in Standalone version
Smoking status is now calculated once per loop instead of once per patient
Cumulative Event rate output for events has been replaced with Event rate and Long-term history rate
Diabetes related death has been separated into a separate output sheet from other death
A new group column has been added to the Inputs sheet after the ID column. This allows outputs of 2 patient groups to be compared
The Input Checks have been combined into a single sheet
The Excel macros are now digitially signed
We report in Nature Genetics a genome-wide association study for glycemic response to metformin, the most commonly used pharmacological therapy for type 2 diabetes. Our meta-analysis across 3,920 individuals reveals that ATM, a gene known to be involved in DNA repair and cell cycle control, plays a role in glycemic response to metformin.[Link]
Since the first subject was enrolled in December 2008, TECOS has witnessed a number of study milestones. The majority of sites are now actively enrolling patients....[Read more...]
NAVIGATOR was presented as a Late Breaking Clinical Trial on March 14, 2010, at the American College of Cardiology's Scientific Sessions in Atlanta, Georgia. The trial was concurrently published as two publications in the New England Journal of Medicine.[Link]
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010 on-line (10.1056/NEJMoa1001121)
It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance.
In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification....
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010 on-line (10.1056/NEJMoa1001122)
The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.
In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program....
Download a slide deck showing the primary NAVIGATOR results of the effects of nateglinide and valsartan on the incidence of diabetes and cardiovascular events by clicking on the link below.
Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials
Henry Krum, John J.V....
Congratulations to Andrew who has been awarded the title of Professor of General Practice with immediate effect by the University's Recognition of Distinction Committee
The final 4-T results were presented during the "Latest clinical trials" symposium at the IDF World Diabetes Congress in Montreal, Canada on Thursday 22nd October 2009.[Link]
The final three-year results of the 4-T trial will be presented at 11 am EST on Thursday 22nd October 2009 during the IDF World Diabetes Congress late breaking clinical trial session.
An overview of the results and a slide set will be available here on the 4-T web site at 11.30 am EST.
ACE trial holds it's first investigator meeting in China.[Link]
The Executive Committee for the Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS) will accept ancillary study proposals for review. Ancillary studies may provide valuable information beyond that explored in the context of the main trial, and will promote continued academic interest in TECOS.[Link]
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial).
In order to provide more precise estimates of the effects of glucose-lowering on major cardiovascular events, the Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), UKPDS and Veterans Affairs Diabetes Trial (VADT) investigators have established a collaboration to facilitate a formal meta-analysis of the results from each trial and to explore any differences among trials.[Link]
The three-year 4-T Trial last patient visit was completed in July 2009 and the database has been locked. The results will be presented at the International Diabetes Forum (IDF) in Montreal on Thursday 22nd October....[Read more...]
Greater HbA1c reduction may be obtained in type 2 diabetes when insulin is initiated using biphasic or prandial insulin rather than a basal regimen, but with an unquantified risk of hypoglycaemia. Studies with longer follow-up are required to determine the clinical relevance of this finding.[Link]
TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) launched in Europe in June and has recruited 30 participants to date from Hungary, Lithuania & Spain.
Centres in India, South Africa and Canada are now open and are expected to start recruiting shortly.
We have found no convincing evidence to recommend routine use of SMBG by reasonably well-controlled, non-insulin-treated patients with type 2 diabetes. The specific advantages of monitoring identified by patients need to be placed in the context of a decline in compliance in the more intensive monitoring group and, at best, a small reduction in HbA1c....[Read more...]
Corrected an issue on page 17 of the manual (Example #1) where the example incorrectly stated that the age entered should be 60. The correct value is 59....
An International Expert Committee with members appointed by the American Diabetes Association, the European Association for the Study of Diabetes, and the International Diabetes Federation was convened in 2008 to consider the current and future means of diagnosing diabetes in nonpregnant individuals. The report of the International Expert Committee represents the consensus view of its members and not necessarily the view of the organizations that appointed them....[Read more...]
12th and 13th November 2009
The Young Diabetologists Forum (YDF) and the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) have developed an educational programme for year 4 and year 5 SpRs.
This year's two-day programme will be held on the 12th ands 13th November, chaired by Professors Sir George Alberti and Rury Holman....
Fixes a problem in the Macintosh version where male subjects are described as female in the printout, the results printed were, however, correct. The Windows version of the software does not suffer this problem and is therefore not changed.[Link]
A global study, sponsored by Amylin and Lilly, is being planned in conjunction with the Diabetes Trials Unit and the Duke Clinical Research Institute. The trial steering committee will be co-chaired by Professors Rury Holman and Rob Califf.[Link]
Price HC, Coleman RL, Stevens RJ, Holman RR
Diabetologia 2009; 52: 394-97
The aim of this study was to investigate the impact of using a non-diabetes-specific cardiovascular disease (CVD) risk calculator to determine eligibility for statin therapy according to current UK National Institute for Health and Clinical Excellence (NICE) guidelines for those patients with type 2 diabetes who are at an increased risk of CVD (10 year risk ≥20%).
The 10 year CVD risks were estimated using the UK Prospective Diabetes Study (UKPDS) Risk Engine and the Framingham equation for 4,025 patients enrolled in the Lipids in Diabetes Study who had established type 2 diabetes and LDL-cholesterol
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Price HC, Holman RR.
The POPADAD (Prevention Of Progression of Arterial Disease And Diabetes) study did not show a benefit for low-dose aspirin therapy or administration of antioxidants for the primary prevention of cardiovascular disease events in individuals with diabetes and asymptomatic peripheral arterial disease....
Hartweg J, Farmer AJ, Holman RR, Neil A.
PURPOSE OF REVIEW: Hypothesis-generating systematic review of the impact of marine-derived omega-3 polyunsaturated fatty acids (PUFAs) on lipid, glycemic and hematological risk factors in type 2 diabetes using pooled data from randomized controlled trials searched up to 20 September 2008....
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
The Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS) clinical trial launched.[Link]
A new comprehensive online resource listing national expertise in the design and conduct of clinical trials is launched today. The UKCRC Registered Clinical Trials Units website provides, for the first time, centralised information on Clinical Trials Units (CTUs) in the UK with expertise in centrally coordinating multicentre clinical trials from design and development, through to data management, and final analysis....[Read more...]
The ACE trial has received ethics approval from the Oxford Tropical Research Ethics Committee (OXTREC). This independent body, based at Oxford University, specializes in the review of trials which do not recruit in Europe....[Read more...]
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
Robert M. Califf, Mitradev Boolell, Steven M....
The UKPDS 10-year post-trial monitoring results were presented at the 44th EASD meeting in Rome on Wednesday 10th September 2008.
They showed continuing benefit of earlier improved glucose control, with emergent significant risk reductions for myocardial infarction and all-cause mortality, despite loss of within trial blood glucose and antihyperglyaemic therapy differences - a legacy effect....
The results of the UKPDS post-trial monitoring follow-up are being be presented at the 2008 EASD.
See link below for more details.....
Determining the most appropriate components for a composite clinical trial outcome
M. Angelyn Bethel, Rury Holman, Steven M....
The August 2008 issue of Diabetic Medicine includes a UKPDS Supplement, edited by Rury Holman and Peter Watkins. This Supplement contains eleven specially commissioned articles that review many of the contributions that have been made by UKPDS in different areas of interest....[Read more...]
Merck has signed a letter of intent with Oxford Diabetes Trial Unit and Duke Clinical Research Institute to design and conduct a clinical cardiovascular outcomes study with sitagliptin (JANUVIA)[Link]
The Acarbose Cardiovascular Evaluation (ACE) trial was launched on Friday 11th April 2008 at the 10th South China International Congress of Cardiology in Guangzhou, China. ACE is a multi-centre clinical outcome trial coordinated by the Diabetes Trial Unit and run in China with the guidance of an international Steering Committee of diabetologists and cardiologists....[Read more...]
The Diabetes UK (DUK) Banting Memorial Lecture is the highest award bestowed by Diabetes UK. The lecture is awarded to a person internationally recognised for their eminence in the field of diabetes.[Link]
30th and 31st October 2008
The Young Diabetologists Forum (YDF) has joined forces with the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) to develop an educational programme for Year 4 and 5 SpRs.
This year's programme will be held over two days at the end of October and will be chaired by Prof Sir George Alberti and Prof Rury Holman....
Type 2 Diabetes
This interactive Journal feature presents the case of a 55-year-old woman with type 2 diabetes, obesity, and hypertension, together with three possible treatment options and expert opinion on each. Vote on the option you would recommend, and submit a comment about your clinical decision....
Entry of a comma (,) instead of a full stop or period (.) as a decimal point where appropriate for non-English versions of Windows.[Link]
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy : Update regarding the thiazolidinediones
Recommendations for designing tables that report randomized trials
Professor Rury Holman, Director of the Diabetes Trials Unit at Oxford University, has been awarded the 'Outstanding Foreign Investigator Award' by the Japan Society of Diabetic Complications[Link]
Impact of the Metabolic Syndrome on Macrovascular and Microvascular Outcomes in Type 2 Diabetes Mellitus. UKPDS 78
The 4-T One-Year results were presented as a "late breaking trial" at the 43rd EASD meeting in Amsterdam on 21st September 2007.[Link]
Fixes a minor problem running the HOMA Calculator on Windows where the allowed ranges for Insulin, Specific Insulin and C-Peptide would be reported with SI units rather than the alternatives. All calculations remain the same....[Read more...]
Stability of soluble adhesion molecules, selectins and C-reactive protein at various temperatures: implications for epidemiological and large-scale clinical studies
Janine Hartweg, Michael Gunter, Rafael Perera, Andrew Farmer, Carole Cull, Casper Schalkwijk, Astrid Kok, Harry Twaalfhoven, Rury Holman and Andrew Neil
Clinical Chemistry 2007;53:1858-60
Meta-analysis of the effects of omega-3 polyunsaturated fatty acids on lipoproteins, lipolytic action, oxidation, lipid ratios and other emerging lipid cardiovascular risk markers in type 2 diabetes
J. Hartweg, A....
GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.
Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial
Andrew Farmer, Alisha Wade, Elizabeth Goyder, Patricia Yudkin, David French, Anthea Craven, Rury Holman, Ann-Louise Kinmonth, Andrew Neil on behalf of the Diabetes Glycaemic Education and Monitoring Trial Group
British Medical Journal 2007;335:132-6
Changes in Version 1.2Bug Fixes
a) Incorrect handling of updated smoking status risk factor values has been fixed. In version 1.1 past smokers (value 1) were treated as current smokers (value 2), and current smokers were treated as a doubling of the smoking effect....
Framingham, SCORE and DECODE do not provide reliable cardiovascular risk estimates in type 2 diabetes
Ruth L. Coleman, Richard J....
Meta-analysis of the effects of omega-3 poylunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes
J. Hartweg, A....
An Association Analysis of the HLA Gene Region in Latent Autoimmune Diabetes in Adults
M. Desai, E....
The results of the AFORRD trial were presented at the International Diabetes Federation Congress in Cape Town on Thursday 7th December 2006
A copy of the press release is attached.
DREAM drug washout study results released at IDF WDC2006 Cape Town
Paraoxonase2 (PON2) Polymorphisms and Development of Renal Dysfunction in Type 2 Diabetes: UKPDS 76
Calle R, McCarthy MI, Banerjee P, Zeggini E, Cull CA, Thorne KI, Wiltshire S, Terra S, Meyer D, Richmond J, Mancuso J, Milos P, Fryburg D, Holman RR
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH for the ADOPT Study Group
Diabetic Medicine 2006;23:1289-1294
Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73
Wright AD, Cull CA, Macleod KM, Holman RR for the UKPDS Group
Journal of Diabetes and its Complications 2006;20:402-408
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes
Steven E. Kahn, Bernard Zinman, Steven M....
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials
Christoph Stettler, Sabin Allemann, Peter Jüni, Carole A. Cull, Rury R....
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
David M Nathan, John B Buse, Mayer B Davidson, Robert J Heine, Rury R Holman, Robert Sherwin, Bernard Zinman
Published simultaneously in:
Diabetes Care (2006); 29: 1963-1972
Diabetologia (2006); 49: 1711-1721
Assessing the Impact of Visual Acuity on Quality of Life in Individuals With Type 2 Diabetes Using the Short Form-36
Philip M Clarke, Judit Simon, Carole A Cull, Rury R Holman
Diabetes Care 2006; 29: 1506-1511
OBJECTIVE- We sought to ascertain quality-of-life measures and utility values associated with visual acuity in type 2 diabetes.
RESEARCH DESIGN AND METHODS- The Medical Outcome Study Short Form with 36 items (SF-36) was administered to 4,051 individuals with type 2 diabetes who were enrolled in the Lipids in Diabetes Study, and their best attainable vision was determined using an Early Treatment of Diabetic Retinopathy Study chart, expressed as a LogMAR score....
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
The Variable Number of Tandem Repeats Upstream of the Insulin Gene Is a Susceptibility Locus for Latent Autoimmune Diabetes in Adults
Minal Desai, Eleftheria Zeggini, Virginia A. Horton, Katharine R....
Risk Factors for Renal Dysfunction in Type 2 Diabetes : UK Prospective Diabetes Study 74
Ravi Retnakaran, Carole A. Cull, Kerensa I....
Beyond The Boundary
Cutting Edge Issues for Emerging Diabetologists.
Venue: 26-27th October 2006, Eynsham Hall, Oxford
This joint OCDEM and Servier meeting is for specialist registrars who are within two years of completing their training in diabetes and seeking to practice as a consultant....
Oxford University researchers and the Oxford Radcliffe Hospitals Trust will lead one of eight new Local Research Networks for diabetes across the UK, working with hospitals and patients throughout the Thames Valley area to develop prevention methods and treatments for diabetes.
The national Diabetes Research Network, with its eight dedicated Local Research Networks, was announced last week by the Department of Health and the UK Clinical Research Network....
Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective
Rury R. Holman
Metabolism Clinical and Experimental 55 (Suppl 1) (2006) S2-S5
The United Kingdom Prospective Diabetes Study shows sulfonylureas to be an effective first-line therapy for people with type 2 diabetes mellitus....
Lancet 2006; 367:25-26
RR Holman, R Retnakaran, A Farmer and R Stevens
The PROactive study has provided an exploratory estimate of the relative risk reduction attributable to pioglitazone for a composite endpoint of all-cause mortality, non-fatal myocardial infarction, and stroke. Although this secondary endpoint was not prespecified and is not significant when adjusted for multiple testing, it is of interest because of the possibility that the observed 16% relative risk reduction might not be mediated through established macrovascular risk factors such as blood pressure, lipids, and glycaemia....
The UKPDS Outcomes Model manual is now available online providing a more detaile view of its functionality and likely uses.[Link]
Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study
Non-HDL Cholesterol Is Less Informative Than the Total-to-HDL Cholesterol Ratio in Predicting Cardiovascular Risk in Type 2 Diabetes
Rury R. Holman, Ruth L....
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes
Michael N Cook, Cynthia J Girman, Peter P Stein, Charles M Alexander & Rury R Holman
Diabetes Care (2005); 28: 995-1000
OBJECTIVE— To describe the course and predictors of glycemic control among patients with type 2 diabetes after sulfonylureas (SUs) are added to metformin (MF).
RESEARCH DESIGN AND METHODS— Patients (n 2,220) treated with MF monotherapy for 90 days before initiating MF plus SU combination therapy between January 1998 and March 2004 were studied in a retrospective analysis of electronic medical records from U....
Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes
Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).
Framingham risk equations underestimate coronary heart disease risk in diabetes
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
Cull CA, Neil HA, Holman RR
Diabetic Medicine 2004; 21:1368-71
AIMS: To examine the proportion of UK Prospective Diabetes Study (UKPDS) patients with Type 2 diabetes taking aspirin regularly for the primary and secondary prevention of cardiovascular disease (CVD) before and after publication of the 1997 American Diabetes Association (ADA) Clinical Practice Recommendations and the 1998 Joint British Recommendations on the Prevention of Coronary Disease in Clinical Practice. METHODS: UKPDS annual review data from 1996/7 (n = 3190) and 2000/1 (n = 2467) were used to determine the prevalence of patients taking aspirin regularly in relation to known CVD risk factors and pre-existing CVD....
Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe
Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; ADOPT Study Group
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group....
The Atorvastatin in Factorial with Omega-3 fatty acids Risk Reduction in Diabetes (AFORRD) study began recruiting participants on Monday 1st November 2004. AFORRD is assessing the degree to which a statin and/or omega-3 fatty acids are likely to reduce coronary heart disease (CHD) risk in people with Type 2 diabetes....[Read more...]
The Treating To Target in Type 2 Diabetes (4-T) study began recruiting participants on Monday 1st November 2004.
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS 68)
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial
Gerstein HC, Yusuf S, Holman RR, Bosch J, Pogue J; The DREAM Trial Investigators
AIMS/HYPOTHESIS: Diabetes is a rapidly rising independent risk factor for atherosclerosis and serious illness. This risk can be reduced by lifestyle changes and/or various drugs....
The HOMA Calculator has been updated to provide HOMA2 IR values automatically, in addition to HOMA2 %S and HOMA2 %B. Fixes a problem running the HOMA Calculator on Windows 98.[Link]
The HOMA Calculator provides quick and easy access to the HOMA model for researchers who wish to use model-derived estimates of beta cell function ( %B), insulin sensitivity (%S) or insulin resistance (HOMA IR), rather than linear approximations. It runs on a variety of computer platforms and can be downloaded from this site[Link]
Version 2.0 of the UKPDS Risk Engine provides separate risk estimates and 95% confidence intervals for fatal coronary heart disease and for fatal stroke. Printing for MacOS and Windows has been improved and support has been added for PocketPC machines.[Link]
A Standardized Triglyceride and Carbohydrate Challenge.
Nina Mohanlal, Rury Holman
Diabetes Care (2004) 27: 89-94
OBJECTIVE— A standardized method of assessing postprandial triglyceride changes is not available....
The Atorvastatin in Factorial with Omega-3 fatty acids Risk Reduction in Diabetes (AFORRD) study is assessing the degree to which a statin and/or omega-3 fatty acids are likely to reduce coronary heart disease (CHD) risk in people with Type 2 diabetes. This 1000 patient, one-year study is being conducted by the Diabetes Trials Unit in an academic collaboration with Pfizer UK.[Link]
Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes.
Fixes a minor issue with the help button on machines using Internet Explorer as the default browser on the Windows platform. Suppresses innapropriate reporting of risk estimated for subjects aged less than 20 at diagnosis.[Link]
The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65)
Poor pregnancy outcome for women with Type 2 diabetes.
Accepts lipid levels in mg/dl as well as mmol/l. Provides a graphical display of risk estimates....[Read more...]
Autoantibodies to the islet cell antigen SOX-13 are associated with duration but not type of diabetes.
On Monday 24th February we moved into our new, purpose built, Oxford Centre for Diabetes, Endocrinology and Metabolism.[Link]
UKPDS 64 Development and Progression of Nephropathy in Type 2 Diabetes: Observation and Modelling from the United Kingdom Prospective Diabetes Study
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR
Kidney International (2003); 63: 225-232
BACKGROUND: The progression of nephropathy from diagnosis of type 2 diabetes has not been well described from a single population. This study sought to describe the development and progression through the stages of microalbuminuria, macroalbuminuria, persistently elevated plasma creatinine or renal replacement therapy (RRT), and death....
The results of the ISAT trial have been published in The Lancet[Link]
The Diabetes Trials Unit has set up a EuroDREAM project office to help manage those european clinical centres that are participating in the DREAM study.[Link]
UKPDS 60 Risk of stroke in type 2 diabetes estimated by the UKPDS risk engine
Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HAW, Holman RR
Stroke (2002); 33: 1776-1781
Retinopathy in Type 2 Diabetes - When Does the Clock Start Ticking? Rury R Holman, Susan E Manley, Andrew E Neil, David R Matthews and Irene M Stratton. Diabetes 2002; 51: Supplement (2) A64
Changing Aspirin Use in the UK Patients with Type 2 Diabetes....
Professor Mark McCarthy, currently Professor of Genomic Medicine at Imperial College, London and Honorary Consultant Physician at St Mary's Hospital, has been elected to the newly created Robert Turner Professorship of Diabetic Medicine.
The Chair, which has been endowed by Servier Laboratories, will be attached to the Oxford Centre for Diabetes, Endocrinology and Metabolism(OCDEM)....
A list of frequently asked questions (FAQ) and answers is now available.[Link]
Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.
Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton I, Jacques P, Breteler MM, Holman R
Journal of Cardiovascular Risk 2001; 8(6): 363-9
Following the withdrawal of cerivastatin by Bayer in August 2001, the Lipids in Diabetes Study (LDS) was put on hold and the 4191 randomised subjects asked to stop all study medication temporarily. In light of this, and the release of the Heart Protection Study (HPS) results, major efforts were made to restart the LDS using a modified design....[Read more...]
Version 1.0 of the UKPDS Risk Engine provides risk estimates and 95% confidence intervals for both coronary heart disease and stroke in individuals with type 2 diabetes not known to have heart disease. These can be calculated for any given duration of type 2 diabetes based on current age, sex, ethnicity, smoking status, presence or absence of atrial fibrillation and levels of HbA1c, systolic blood pressure, total cholesterol and HDL cholesterol.[Link]
The results of the FHS trial where presented at the EASD meeting in Jerusalem.
Randomised controlled trial of sulphonylurea therapy for subjects with increased fasting glucose levels
FHS group, Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR
Randomised controlled trial of enforced healthy-living advice in subjects with increased but not diabetic fasting glucose
Fasting hyperglycaemia Study Group, Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC
Subject Identification and Recruitment for a non-insulin-dependent diabetes prevention trial
Fasting Hyperglycaemia Study group, Hammersley MS, Meyer LC, Morris RJ, Manley SE